Welcome to our dedicated page for Precision Optics news (Ticker: POCI), a resource for investors and traders seeking the latest updates and insights on Precision Optics stock.
Precision Optics Corporation, Inc. reports recurring business developments in advanced optical instruments for the medical and defense/aerospace industries. The company designs, develops and manufactures custom optical medical devices, endoscopes, endocouplers and related optical assemblies, with news frequently covering single-use endoscopy programs and customer production orders.
Updates for POCI also include product-development work for aerospace and defense applications, including small-diameter borescope systems used in jet-engine inspection. Company announcements commonly address fiscal-period operating results, conference calls, customer program activity, backlog and pipeline commentary, and capital-structure actions involving its Nasdaq-listed common stock.
Precision Optics (Nasdaq:POCI) will present at the Planet MicroCap Las Vegas 2026 Investor Conference on Wednesday, June 17, 2026, at 11:00 a.m. Pacific time at the Bellagio Resort & Hotel in Las Vegas.
The presentation will be available via live webcast, and management will also hold in-person 1x1 investor meetings on June 17-18 for registered conference attendees.
Precision Optics (Nasdaq: POCI) will participate in the virtual Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The Company will host a webcast presentation and conduct one-on-one investor meetings.
The webcast is scheduled for 1:00 p.m. ET and will be available for replay after the event.
Precision Optics (NASDAQ:POCI) reported record Q3 FY2026 revenue of $8.7 million, up about 108% year-over-year, with production revenue at $7.6 million and engineering revenue at $1.1 million. Gross margin rose to 23.6%, net loss narrowed to $0.1 million, and adjusted EBITDA was $0.3 million.
The company raised FY2026 revenue guidance to $29–$31 million and tightened adjusted EBITDA guidance to a loss of $2.5–$2.7 million. It completed an oversubscribed $10 million public offering and received a $3.5 million follow-on ophthalmic order.
Precision Optics (Nasdaq: POCI) scheduled its Q3 fiscal 2026 earnings conference call for Wednesday, May 13, 2026 at 5:00 p.m. ET. The company will release financial results and file its 10-Q after market close on May 13, 2026, followed by the call.
Call access includes dial-in numbers, a live webcast, and seven-day teleconference and webcast replays.
Precision Optics (NASDAQ: POCI) received a follow-on production order of approximately $3.5 million for a single-use ophthalmic endoscope. Shipments are expected to commence shortly and be fulfilled over 12–15 months, supporting the customer’s transition from limited launch to full launch.
The program is Precision Optics’ second single-use design to enter production and follows an initial production order announced in November 2024. Management cites multi-year development and IP investments as enabling the shift to single-use endoscopy.
Precision Optics (NASDAQ: POCI) priced an upsized underwritten public offering of 2,777,777 shares at $3.60 per share, generating roughly $10.0 million of gross proceeds. The underwriter has a 45‑day option to buy up to 416,667 additional shares. The offering is expected to close on or about March 30, 2026, and net proceeds will be used for working capital and general corporate purposes. Insiders including the CEO, CFO and COO participated at the public price. Lucid Capital Markets is sole book‑running manager.
Precision Optics (NASDAQ: POCI) announced on March 26, 2026 that it is commencing an underwritten public offering of common stock (or common stock equivalents), subject to market conditions and with no assurance as to timing, size, or terms.
Lucid Capital Markets is the sole book-running manager, and the offering is being made under a shelf registration on Form S-3 declared effective June 14, 2024; a preliminary prospectus supplement will be filed with the SEC.
Precision Optics (NASDAQ: POCI) reported Q2 FY2026 revenue of $7.37 million, a quarterly record and ~63% year-over-year increase, driven by $6.4 million in production revenue (+105% YoY). Gross margin fell to 2.8% from 23.6% prior-year. Net loss was $1.78 million and adjusted EBITDA was $(1.5) million. The company guided FY2026 revenue to $26–28 million (36%–47% growth) and adjusted EBITDA to $(2.5)–$(3.0) million. Management cited operational investments and ramp-related inefficiencies with expected margin improvement in H2.
Precision Optics (Nasdaq: POCI) will discuss second quarter fiscal 2026 results on Tuesday, February 17, 2026 at 5:00 p.m. ET. The company intends to release results and file its 10-Q after market close, followed by the conference call.
Access by phone at (844) 735-3662 or (412) 317-5705, or via live webcast at https://app.webinar.net/Zo5aLdzPzmg. A teleconference replay will be available for seven days at (855) 669-9658 or (412) 317-0088 (replay access code 3100136); a webcast replay will also be posted at the same URL.
Precision Optics (NASDAQ: POCI) reported Q1 fiscal 2026 results for the quarter ended September 30, 2025, with record revenue of $6.68M (up ~59% year-over-year) driven by production deliveries. Production revenue rose to $6.0M (up ~133% YoY) while engineering revenue fell to $0.7M (down 59% YoY). Gross margin declined to 14.2% from 26.6% a year earlier. Net loss was $1.64M and Adjusted EBITDA was $(1.2)M for the quarter. Recent wins include two development agreements worth $700k and $678k. Fiscal 2026 guidance projects revenue to exceed $25M (≈31% growth) and Adjusted EBITDA of about $0.5M.